Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.
Also called NCT02010905
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT02010905
-
- Other papers using this trial's data
- Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Netherlands
- Registry status
- Unknown status
Technical summary
Registry record NCT02010905. Randomized; quadruple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2018-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
- Acronym
- Redefine
- Condition
- Tetralogy of Fallot
- Condition
- Heart Defects, Congenital
- Condition
- Ventricular Dysfunction, Right
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Placebo
- Lead sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Collaborator
- The Interuniversity Cardiology Institute of the Netherlands
Record details
- Record id
cardio:ct-nct02010905- Content hash
800f9d22a63ae876c4fb45e697613f7d1438efe226e5dd081130ebd4f600cc02